Lonza - Lifescience-Konzern (Seite 3)
eröffnet am 27.09.17 13:06:37 von
neuester Beitrag 23.03.24 16:01:59 von
neuester Beitrag 23.03.24 16:01:59 von
Beiträge: 77
ID: 1.262.877
ID: 1.262.877
Aufrufe heute: 1
Gesamt: 10.454
Gesamt: 10.454
Aktive User: 0
ISIN: CH0013841017 · WKN: 928619
520,30
EUR
-1,05 %
-5,50 EUR
Letzter Kurs 15:48:24 Lang & Schwarz
Neuigkeiten
17.04.24 · wO Newsflash  |
17.04.24 · EQS Group AG |
30.03.24 · wO Chartvergleich |
23.03.24 · wO Chartvergleich |
Werte aus der Branche Chemie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1.650,00 | +716,83 | |
| 103,54 | +19,99 | |
| 1,3000 | +18,18 | |
| 1.964,50 | +11,98 | |
| 84,26 | +11,31 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 19.600,00 | -9,68 | |
| 1,7600 | -10,66 | |
| 37,05 | -12,37 | |
| 5,6900 | -26,68 | |
| 43,02 | -60,46 |
Beitrag zu dieser Diskussion schreiben
FeedbackLONZA KOOPERATIONSPARTNER MODERNA ERREICHT WEITEREN MEILENSTEIN
Die gute Nachricht von Moderna wird sicher auch Lonza weiter antreiben:https://www.deraktionaer.de/artikel/pharma-biotech/breaking-…
Antwort auf Beitrag Nr.: 63.533.564 von faultcode am 01.05.20 20:56:12Lonza im Moderna-Hype:
Currency in CHF
https://finance.yahoo.com/quote/LONN.SW/?p=LONN.SW
Currency in CHF
https://finance.yahoo.com/quote/LONN.SW/?p=LONN.SW
1.5.
Moderna, Switzerland's Lonza strike deal on potential COVID-19 vaccine
https://finance.yahoo.com/news/moderna-switzerlands-lonza-st…
...
Moderna Inc and Swiss contract drugmaker Lonza Group AG said on Friday they would accelerate the manufacturing of the U.S. drug developer's potential coronavirus vaccine.
The announcement comes at a time when drugmakers are pausing clinical trials for other disease areas as they focus on testing potential treatments for the coronavirus.
The experimental vaccine, mRNA-1273, is being tested in early-stage trial by the U.S. National Institutes of Health, with Moderna expecting to begin mid-stage trial in the second quarter.
Under the 10-year collaboration agreement, the companies aim to manufacture up to a billion doses per year as technology transfer is expected to begin in June, and the first batches of the vaccine are expected to be manufactured in Lonza U.S. in July.
"Over time, the parties intend to establish additional production suites across Lonza's worldwide facilities, ultimately allowing for the manufacture of material equivalent to up to 1 billion doses of mRNA-1273 per year for use worldwide", the statement added.
The disease, which infected more than 3.2 million people worldwide and killed around 232,000, set off a race among drugmakers to find an antidote.
Earlier this month, Moderna got a $483 million funding from a U.S. government agency to accelerate its COVID-19 vaccine development.
Separately, Basel-based Lonza's pharmaceuticals, biotech and nutrition business has received more than 40 enquiries regarding projects relating to COVID-19, the company said earlier in April.
...
Moderna, Switzerland's Lonza strike deal on potential COVID-19 vaccine
https://finance.yahoo.com/news/moderna-switzerlands-lonza-st…
...
Moderna Inc and Swiss contract drugmaker Lonza Group AG said on Friday they would accelerate the manufacturing of the U.S. drug developer's potential coronavirus vaccine.
The announcement comes at a time when drugmakers are pausing clinical trials for other disease areas as they focus on testing potential treatments for the coronavirus.
The experimental vaccine, mRNA-1273, is being tested in early-stage trial by the U.S. National Institutes of Health, with Moderna expecting to begin mid-stage trial in the second quarter.
Under the 10-year collaboration agreement, the companies aim to manufacture up to a billion doses per year as technology transfer is expected to begin in June, and the first batches of the vaccine are expected to be manufactured in Lonza U.S. in July.
"Over time, the parties intend to establish additional production suites across Lonza's worldwide facilities, ultimately allowing for the manufacture of material equivalent to up to 1 billion doses of mRNA-1273 per year for use worldwide", the statement added.
The disease, which infected more than 3.2 million people worldwide and killed around 232,000, set off a race among drugmakers to find an antidote.
Earlier this month, Moderna got a $483 million funding from a U.S. government agency to accelerate its COVID-19 vaccine development.
Separately, Basel-based Lonza's pharmaceuticals, biotech and nutrition business has received more than 40 enquiries regarding projects relating to COVID-19, the company said earlier in April.
...
bissel Gentherapie kommt hinzu:
Lonza übernimmt klinische Fertigung für Rocket Pharmaceuticals
https://www.finanzen.ch/nachrichten/aktien/lonza-uebernimmt-…
Lonza übernimmt klinische Fertigung für Rocket Pharmaceuticals
https://www.finanzen.ch/nachrichten/aktien/lonza-uebernimmt-…
Trading Spotlight
Antwort auf Beitrag Nr.: 62.435.190 von pickuru am 21.01.20 08:57:28
Ja die Aktie sorgt immer für good News.. heisst oft für positive Überraschungen - das Long Invest vzahlz sich aus seit 2016.....ich mag Schweizer Aktien .....insbesondere in solchen Marktphasen wie dieser...
Oberkassel
Börse feiert die Zahlen von Lonza mit deutlichem Kursgewinn der Aktie
https://www.cash.ch/news/top-news/gesundheitsbranche-boerse-…Ja die Aktie sorgt immer für good News.. heisst oft für positive Überraschungen - das Long Invest vzahlz sich aus seit 2016.....ich mag Schweizer Aktien .....insbesondere in solchen Marktphasen wie dieser...
Oberkassel
Bei Lonza läuft das Geschäft besser als gedacht
https://www.cash.ch/news/top-news/gesundheitsbranche-bei-lon…
https://www.cash.ch/news/top-news/gesundheitsbranche-bei-lon…
Antwort auf Beitrag Nr.: 61.897.496 von faultcode am 12.11.19 08:47:01
Das ist wirklich eine Überraschung, der Kurs reagiert zur Zeit extremer, wird sich aber wieder erholen.
Bleibe bei dem Invest Lonza Top Long Invest.
Oberkassel
Das ist ein Tiefschlag für Lonza
https://www.cash.ch/news/top-news/ceo-funk-geht-ueberraschen…Das ist wirklich eine Überraschung, der Kurs reagiert zur Zeit extremer, wird sich aber wieder erholen.
Bleibe bei dem Invest Lonza Top Long Invest.
Oberkassel
Antwort auf Beitrag Nr.: 61.094.071 von faultcode am 24.07.19 11:47:26
Basel, Switzerland, 12 November 2019 – – Lonza announced today that Marc Funk, CEO, will leave the Company for personal reasons. The Board of Directors also announced that Albert Baehny, Chairman, will take on the additional responsibility of Chief Executive Officer on an ad interim basis until a permanent successor is found. Marc will stay until January 2020 to ensure a smooth hand-over.
In addition, for reasons of good governance, board member Christoph Maeder has been appointed Lead Independent Director by the Board.
Christoph Maeder, Lead Independent Director said: “Albert has agreed to lead the Company on a temporary basis until a successor is in place, for which a search has commenced. The Board respects Marc’s decision and would like to thank him for his service to Lonza and wish him well for his future endeavors.”
Albert Baehny, Chairman said: “I am committed to Lonza, its employees and all its stakeholders and I will ensure that I work in their best interests in the months ahead. The Company has an exciting future in dynamic markets and I am keen to ensure that we maintain our momentum and capture all the opportunities available to us. I look forward to working with colleagues, customers, partners and other stakeholders in the coming months and also to working with the Board in the search for a new Chief Executive Officer to lead the Company in the years ahead.”
CEO schmeisst hin
Board AnnouncementBasel, Switzerland, 12 November 2019 – – Lonza announced today that Marc Funk, CEO, will leave the Company for personal reasons. The Board of Directors also announced that Albert Baehny, Chairman, will take on the additional responsibility of Chief Executive Officer on an ad interim basis until a permanent successor is found. Marc will stay until January 2020 to ensure a smooth hand-over.
In addition, for reasons of good governance, board member Christoph Maeder has been appointed Lead Independent Director by the Board.
Christoph Maeder, Lead Independent Director said: “Albert has agreed to lead the Company on a temporary basis until a successor is in place, for which a search has commenced. The Board respects Marc’s decision and would like to thank him for his service to Lonza and wish him well for his future endeavors.”
Albert Baehny, Chairman said: “I am committed to Lonza, its employees and all its stakeholders and I will ensure that I work in their best interests in the months ahead. The Company has an exciting future in dynamic markets and I am keen to ensure that we maintain our momentum and capture all the opportunities available to us. I look forward to working with colleagues, customers, partners and other stakeholders in the coming months and also to working with the Board in the search for a new Chief Executive Officer to lead the Company in the years ahead.”
Durchsuchen
02.04.24 · wO Newsflash · Lonza Group |
02.04.24 · EQS Group AG · Lonza Group |
30.03.24 · wO Chartvergleich · ABB |
23.03.24 · wO Chartvergleich · Carl Zeiss Meditec |